[Cardiotoxicity from anti-HER-2 therapies in patients with HER-2 positive breast cancer].
Natalia Camejo-MartínezCecilia Castillo-LeskaValeria Rodríguez-SaenzGuadalupe HerreraDahiana Lourdes Amarillo-HernándezMaría Carolina Dörner-CabreraGabriel David Krygier-WaltierPublished in: Revista medica del Instituto Mexicano del Seguro Social (2024)
The study showed a cardiotoxicity incidence similar to the international one. Most did not present cardiac toxicity, and if they did, it was asymptomatic and reversible.